Royalty Pharma

Founded in 1996, Royalty Pharma is a leading player in the pharmaceutical industry, specialising in acquiring biopharmaceutical royalties. The firm plays a pivotal role in funding innovation within the sector, allowing companies to unlock value from their intellectual property. Based in New York, Royalty Pharma has established itself as a key financial partner for many healthcare enterprises worldwide.

Through its unique business model, Royalty Pharma has built a diverse portfolio of royalties, partnering with academic institutions, research hospitals, and pharmaceutical companies. By providing capital to these entities, it supports the development of groundbreaking drugs and treatments. The company’s strategy focuses on high-potential therapeutic areas, ensuring a robust and balanced portfolio that drives sustained growth.

Under the leadership of CEO Pablo Legorreta, Royalty Pharma continues to innovate and expand its reach. The company remains committed to fostering advancements in medical research, aiming to improve patient outcomes and address unmet medical needs. As a leader in royalty transactions, Royalty Pharma leverages its expertise to create value across the pharmaceutical landscape.